医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evaluate Ltd’s Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In

2017年07月20日 PM10:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & SAN FRANCISCO & TOKYO

Today life science commercial intelligence leader, Evaluate, released case studies highlighting the value of granular patient segmentation and epidemiological data to support commercial valuations, whitespace identification and product differentiation ultimately leading to enhanced portfolio decision-making. Therapy areas covered include: CAR-T, MPS-III and Age-related Macular Degeneration.

According to report author and Evaluate Senior Analyst Chris Watson, PhD, the last 5 years have witnessed a significant re-organisation of the pharmaceutical business model around the ability to identify, develop and bring to market novel therapies with proven clinical benefits in very well defined patient populations.

“Within this rapidly changing environment, Evaluate is supporting our clients with pioneering approaches to risk / value assessments and forecasting, aimed to improve the quality and speed of analysis for strategic decisions”, said Antonio Iervolino, Head of Forecasting at Evaluate.

The case studies provide practical examples aimed at competitive intelligence, business developers, corporate strategists and executive decision-makers and demonstrate the value to these roles of convenient, high quality epidemiology data used in conjunction with global commercial intelligence.

Epi Analyzer, brings together Evaluate’s expertise in consensus forecasts with a highly granular epidemiology database. Its coverage includes over 160 diseases and 8,000 subpopulations with the ability to drill down to very specific patient pools. To learn more and download the case studies report, please visit: www.evaluate.com/EpiAnalyzerReport2017.

###

About Evaluate

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epvantage. On Instagram: Evaluateltd.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170720005689/en/

CONTACT

Media Contacts:
Evaluate and EP Vantage (for general
questions)
Christine Lindgren
+1 617-866-3906
christine.lindgren@evaluategroup.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Harris/Melanie Toyne Sewell
+44
(0) 20 7457 2020
evaluate@instinctif.com
or
Jani
Communications (for U.S. media)
Janice Foley
+1-617-823-5555
janifoley@verizon.net
or
Edelman
Japan KK
Yamada/Masaki
TEL: +81(3)-4360-9000
Email: EvaluateJapanPR@edelman.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Bioasis Announces Registration and Grant Notice of Patent Application in China Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier
  • U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer
  • Fitbit Collaborates with Singapore’s Health Promotion Board on Population-Based Public Health Initiative in Singapore
  • Evidera and CSS Collaborate to Develop Joint Real-world and Patient-centered Research Capabilities in Japan
  • Propanc Biopharma Receives Granted US Patent Covering Additional Composition Claims for PRP